Table 1 The characteristics of included trials
Study | Country of publication | Country of patients | Experimental Sample size | Control Sample Size | Age | Duration of diabetes | Intensive Therapy | Control therapy | Follow-up |
|---|---|---|---|---|---|---|---|---|---|
Adrian F Hernandez 2018 [10] | USA | Western Europe Eastern and central Europe North America Latin America Asia Pacific | 4731 | 4732 | 64.2/ 64.2 | 4.1/ 4.2 | Albiglutide (30-50mg) once a week | Placebo once a week | 1.5 years |
Rury R. Holman 2017 [4] | United Kingdom | Europe, Latin America Europen subcategories, Asia-pacific, Eastern Europe, Western Europe, North America | 7356 | 7396 | <65y 8813 ≥65y 5939 | 12.0 (7.0-18.0) | exenatide at a dose of 2 mg once weekly | Placebo once a week | 2.3 years |
Steven P2016 [7] | USA | North AmericaEurope Asia Rest of the world | 4668 | 4672 | <60y 2321 ≥60y 7019 | 12.8 years | liraglutide 1.8 mg (or the maximum tolerated dose) once daily | placebo once daily | 3.8 years |
Steven P. Marso2016 [8] | United Kingdom | 230 sites in 20 countries. | 1648 | 1649 | 64.6± 7.4 | 13.9± 8.1 | semaglutide (0.5mg or 1.0mg) once a week | Placebo once a week | 109 weeks |
Preffer MA 2015 [3] | Thailand | 49 countrirs | 3034 | 3034 | 60.3 | 9.3 | lixisenatide | placebo | 2.1 years |
Gerstein HC 2019 [9] | UK | 371 sites 24 countries | 4949 | 4952 | 66.2 | 10.5/ 9.5 | dulaglutide 1.5mg | placebo | 5.4 years |